Cost-effectiveness of use of the GlucoWatch® Biographer in children and adolescents with type 1 diabetes: A preliminary analysis based on a randomized controlled trial

Pediatric Diabetes

Volumn 4, Issue 2, 2003, Pages 82-86

  Eastman, Richard C ^a   Leptien, Amy D ^a   Chase, H Peter ^b  

^a Cygnus Therapeutic Systems   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cost utility; Diabetes; Glucose; Glucowatch Biographer; Monitors

Indexed keywords

INSULIN;

ARTICLE; BLINDNESS; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EQUIPMENT; HEALTH CARE COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; KIDNEY FAILURE; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SIMULATION;

ADOLESCENT; BLINDNESS; CHILD; COLORADO; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MACULAR DEGENERATION; MEDICAL RECORDS; TIME FACTORS;

EID: 0038387800     PISSN: 1399543X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5448.2003.00011.x     Document Type: Article

References (12)

1. Tamada JA, Garg SK, Jovanovic L et al. Non-invasive glucose monitoring: Comprehensive clinical results. JAMA 1999: 282: 1839-1844.
2. Tierney MJ, Tamada JA, Potts RO et al. The GlucoWatch biographer: a frequent, automatic and non-invasive glucose monitor. Ann Med 2000: 32: 632-641.
3. Chase H, Peter Wightman C, Klingensmith G et al. Use of the GlucoWatch® Biographer in children with type 1 diabetes. Pediatrics 2003: 111: 790-794.
4. The Diabetes Control And Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996: 276: 1409-1415.
5. Meltzer D, Egleston B, Stoffel D, Dasbach E. Effect of future costs on cost-effectiveness of medical interventions among young adults. Med Care 2000: 38: 679-685.
6. Thomson Medical Economics. 2002 Red Book. Thomson Medical Economics, Montvale, NJ, 2002.
7. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Can Med Assoc J 1992: 146: 473-481.
8. Robinson R. Economic evaluation and health care. What does it mean? BMJ 1993: 307: 670-673.
9. The CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002: 287: 2542-2551.
10. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000: 23: 390-404.
11. The Diabetes Control And Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
12. Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997: 20: 735-744.